drugset / Trial / NCT00306514

Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients

NCT00306514 ↗

Phase 1/2 Completed Cytos Biotechnology AG
RandomizedParallel-groupOpen-label

Summary

The purpose of this study is to evaluate whether vaccination with a Melan-A VLP vaccine leads to a specific cellular immune response in patients with malignant melanoma at advanced stage of the disease.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject CYT004-MelQbG10 Vaccine — —

Indications